SS-31 Study Explained: Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced

Quick answer

In laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹

The result belongs to the exact population, outcome, and design described in the source. For Filipino readers, that makes SS-31 an evidence question first and a separate product-verification question second. That order keeps the short answer useful without turning it into personal guidance or a sales promise. That keeps the answer specific and easy to check.

What is SS-31, in plain language?

The most useful conclusion about SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast is the one another reader can retrace. The citation should lead back to the exact result described here.

The paper’s main result was that in laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹

The study context keeps the conclusion precise: one study showed SS-31 reduced senescence-associated beta-galactosidase staining from 67% to 38% in irradiated H9C2 cells. Another showed SS-31 partially attenuated doxorubicin-induced SA-β-gal staining from 51.4% to 35.8%.¹

That result does not erase its main limit: these are cell-culture studies and do not represent human outcomes.¹

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the central study report?

This is where the SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast headline needs context. The study design explains what the result can carry and where the interpretation should stop.

The central finding was specific: the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.²

That result came from this context: the MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.²

The finding should stop here: this was the overall result for a genetically diverse population.²

What does the wider evidence add?

For Filipino readers, SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast is clearest when the global research and the exact local record remain separate checks.

The source describes a focused result: in laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹

The population and method are part of the answer: one study showed SS-31 reduced senescence-associated beta-galactosidase staining from 67% to 38% in irradiated H9C2 cells. Another showed SS-31 partially attenuated doxorubicin-induced SA-β-gal staining from 51.4% to 35.8%.¹

The source also narrows the conclusion: these are cell-culture studies and do not represent human outcomes.¹

Which limits matter most?

Readers do not need a technical background to follow SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast. They do need the study context in plain language and a clear explanation of the main limit.

The paper’s main result was that the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.²

The study context keeps the conclusion precise: the MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.²

That result does not erase its main limit: this was the overall result for a genetically diverse population.²

How does the catalog identity fit?

The most useful conclusion about SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast is the one another reader can retrace. The citation should lead back to the exact result described here.

The central finding was specific: SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.³

That result came from this context: the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.³

The finding should stop here: this is a description of its mechanism of action from regulatory and laboratory sources.³

Researchers found that in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.⁴ One caution belongs beside that result: this was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁴

The source describes a focused result: WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁵ The source also narrows the conclusion: appearance alone cannot authenticate a product or establish a research outcome.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers take away?

This is where the SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast headline needs context. The study design explains what the result can carry and where the interpretation should stop.

The source describes a focused result: in a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁶

The population and method are part of the answer: the FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁶

The source also narrows the conclusion: the snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁶

The measured outcome was clear: the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁷ The practical limitation is this: a portal record applies to the exact product or establishment named in that record.⁷

Bottom line

The clearest reading is that in laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹

This is a description of its mechanism of action from regulatory and laboratory sources.³ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

For this SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast question, the strongest conclusion is the one that keeps the cited outcome and its original setting together.

Frequently asked questions

What is the short answer about SS-31?

The cited source gives a focused answer: in laboratory studies on heart muscle cells, SS-31 reduced markers of cellular senescence induced by radiation and by the chemotherapy drug doxorubicin.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

No. This is a description of its mechanism of action from regulatory and laboratory sources.³ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.² Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.³ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this SS-31 study on Mitochondrial-Targeted Attenuates Doxorubicin-Induced Cardiomyoblast guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.; Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.. One study showed SS-31 reduced senescence-associated beta-galactosidase staining from 67% to 38% in irradiated H9C2 cells. Another showed SS-31 partially attenuated doxorubicin-induced SA-β-gal staining from 51.4% to 35.8%. These are cell-culture studies and do not represent human outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

2. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24. This was the overall result for a genetically diverse population. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩²

5. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³

7. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

8. Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.; Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.; FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩